Germany · Delayed Price · Currency is EUR Level Bio AB Statistics
Total Valuation
Level Bio AB has a market cap or net worth of EUR 2.02 million. The enterprise value is 1.88 million.
| Market Cap | 2.02M |
| Enterprise Value | 1.88M |
Important Dates
The next estimated earnings date is Friday, February 20, 2026.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 68.40M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.93% |
| Shares Change (QoQ) | -5.53% |
| Owned by Insiders (%) | 16.23% |
| Owned by Institutions (%) | 13.88% |
| Float | 32.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 12.90 |
| P/TBV Ratio | 88.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.44 |
| EV / Sales | 0.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.83 |
Financial Efficiency
Return on equity (ROE) is -104.88% and return on invested capital (ROIC) is -70.14%.
| Return on Equity (ROE) | -104.88% |
| Return on Assets (ROA) | -17.99% |
| Return on Invested Capital (ROIC) | -70.14% |
| Return on Capital Employed (ROCE) | -170.22% |
| Revenue Per Employee | 274,874 |
| Profits Per Employee | -34,491 |
| Employee Count | 11 |
| Asset Turnover | 2.14 |
| Inventory Turnover | 3.67 |
Taxes
| Income Tax | -31,847 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 49.65 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Level Bio AB had revenue of EUR 2.75 million and -344,914 in losses. Loss per share was -0.01.
| Revenue | 2.75M |
| Gross Profit | 1.47M |
| Operating Income | -369,060 |
| Pretax Income | -376,762 |
| Net Income | -344,914 |
| EBITDA | -266,325 |
| EBIT | -369,060 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 142,370 in cash and n/a in debt, giving a net cash position of 142,370.
| Cash & Cash Equivalents | 142,370 |
| Total Debt | n/a |
| Net Cash | 142,370 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 156,480 |
| Book Value Per Share | 0.00 |
| Working Capital | 32,110 |
Cash Flow
| Operating Cash Flow | -28,001 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 53.64%, with operating and profit margins of -13.43% and -12.55%.
| Gross Margin | 53.64% |
| Operating Margin | -13.43% |
| Pretax Margin | -13.71% |
| Profit Margin | -12.55% |
| EBITDA Margin | -9.69% |
| EBIT Margin | -13.43% |
| FCF Margin | n/a |
Dividends & Yields
Level Bio AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.93% |
| Shareholder Yield | -1.93% |
| Earnings Yield | -17.08% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |